Immunogenicity of Two Efficacious Outer Membrane Protein‐Based Serogroup B Meningococcal Vaccines among Young Adults in Iceland | Zendy

Bradley A. Perkins | Zendy; Kristín Jónsdóttir | Zendy; H. Briem | Zendy; Elwyn Griffiths | Zendy; Bonnie Plikaytis | Zendy; E. Arne Høiby | Zendy; Einar Rosenqvist | Zendy; Jens J. Holst | Zendy; Hanne Nøkleby | Zendy; Franklin Sotolongo | Zendy; Gustavo Sierra | Zendy; H. C. Campa | Zendy; G M Carlone | Zendy; Deniece R. Williams | Zendy; Janet K. Dykes | Zendy; Darrell R. Kapczynski | Zendy; E Tikhomirov | Zendy; Jay D. Wenger | Zendy; Claire V. Broome | Zendy

Open Access

Immunogenicity of Two Efficacious Outer Membrane Protein‐Based Serogroup B Meningococcal Vaccines among Young Adults in Iceland

Author(s) -

Bradley A. Perkins,

Kristín Jónsdóttir,

H. Briem,

Elwyn Griffiths,

Bonnie Plikaytis,

E. Arne Høiby,

Einar Rosenqvist,

Jens J. Holst,

Hanne Nøkleby,

Franklin Sotolongo,

Gustavo Sierra,

H. C. Campa,

G M Carlone,

Deniece R. Williams,

Janet K. Dykes,

Darrell R. Kapczynski,

E Tikhomirov,

Jay D. Wenger,

Claire V. Broome

Publication year - 1998

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/514232

Subject(s) - immunogenicity , meningococcal vaccine , bacterial outer membrane , meningococcal disease , virology , neisseria meningitidis , medicine , microbiology and biotechnology , antibody , biology , immunology , immunization , escherichia coli , bacteria , genetics , gene

Serum bactericidal activity (SBA) and ELISA antibody levels elicited by two efficacious serogroup B meningococcal vaccines were measured in a controlled trial involving 408 15- to 20-year-olds. Subjects were given two doses at a 6-week interval of a serogroup B or control vaccine. Response was defined as > or = 4-fold rise in antibody level. After two doses of the Finlay Institute (Havana) vaccine at 12 months, the proportions of SBA and ELISA responders were not different from those of the control group (15% and 17% [vaccine] vs. 13% and 9% [control], P > .05). After two doses of the National Institute of Public Health (Oslo) vaccine, there were more SBA and ELISA responders than in the control group (47% and 34% [vaccine] vs. 10% and 1% [control]) or the Finlay Institute vaccine group (P < .05 for both). SBA and ELISA may be insensitive correlates for protective efficacy for some outer membrane protein-based serogroup B meningococcal vaccines.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research